CA
BDTX icon

CoreCap Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

CoreCap Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$216 Buy
+120
New +$216 ﹤0.01% 2267
2022
Q3 		– Sell
-120
Closed – – 680
2022
Q2 		$0 Buy
+120
New +$279 ﹤0.01% 2130
2022
Q1 		– Sell
-120
Closed -$1K – 690
2021
Q4 		$1K Buy
+120
New +$838 ﹤0.01% 2053

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

CoreCap Advisors's BDTX Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Black Diamond Therapeutics (BDTX) in Q4 2022: 120 shares worth $216. The stake represents ﹤0.01% of the portfolio and ranks #2267 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in BDTX as recently as Q2 2022.

CoreCap Advisors first reported a position in BDTX in Q4 2021 and has held it in 3 quarters since. The position peaked at $1K in Q4 2021. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

  • CoreCap Advisors held 120 shares of Black Diamond Therapeutics worth $216 as of Q4 2022.
  • Black Diamond Therapeutics was a new CoreCap Advisors position in Q4 2022.
  • Black Diamond Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #2267 holding.
  • CoreCap Advisors first reported a position in Black Diamond Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • CoreCap Advisors's Black Diamond Therapeutics position peaked at $1K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.